CN1733279A - A kind of medicinal composition for the treatment of chronic kidney hypofunction - Google Patents
A kind of medicinal composition for the treatment of chronic kidney hypofunction Download PDFInfo
- Publication number
- CN1733279A CN1733279A CN 200510028973 CN200510028973A CN1733279A CN 1733279 A CN1733279 A CN 1733279A CN 200510028973 CN200510028973 CN 200510028973 CN 200510028973 A CN200510028973 A CN 200510028973A CN 1733279 A CN1733279 A CN 1733279A
- Authority
- CN
- China
- Prior art keywords
- group
- treatment
- gram
- kidney
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属中药领域，具体涉及一种治疗脾虚湿热型慢性肾衰的药物复合物。本发明以中医的健脾益气，清热化湿理论为依据，选用党参(或太子参)、生黄芪(或白术)、草果仁(或砂仁)、苍术(或川扑)、黄连(或车前子)、制大黄(或生大黄)中药为原料制成，经临床和动物实验证实具有降低血肌酐、尿素氮、24小时蛋白尿定量、升高肾小球滤过率，改善肾功能，降低血脂，提高SOD活力、清除氧自由基，调节细胞免疫的功能，影响CRF细胞因子表达和延缓肾纤维化，调节胃肠激素和细胞因子的分泌，调节肾组织水通道蛋白等作用。本发明能改善慢性肾衰患者脾虚湿热症的临床症状，安全，可长期服用。The invention belongs to the field of traditional Chinese medicines, and in particular relates to a drug compound for treating chronic renal failure of spleen deficiency and damp-heat type. The present invention is based on the theory of invigorating the spleen and replenishing qi of traditional Chinese medicine, clearing heat and removing dampness, and selects Codonopsis pilosula (or Radix Pseudostellariae), Raw Radix Astragali (or Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizome), Radix Astragali (or Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizome), Herb Seed (or Amomum), Cangzhu (or Chuanpu), Coptidis ( or psyllium), rhubarb (or raw rhubarb) traditional Chinese medicine as raw materials, clinical and animal experiments have been proved to reduce blood creatinine, blood urea nitrogen, 24-hour proteinuria quantitative, increase glomerular filtration rate, improve kidney function Function, reduce blood lipids, improve SOD activity, scavenge oxygen free radicals, regulate cellular immune function, affect the expression of CRF cytokines and delay renal fibrosis, regulate the secretion of gastrointestinal hormones and cytokines, regulate renal tissue aquaporin, etc. The invention can improve the clinical symptoms of spleen deficiency and damp-heat in patients with chronic renal failure, is safe and can be taken for a long time.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine medicinal composition for the treatment of insufficiency of the spleen damp-heat type chronic renal failure.
Technical background
(chronic renal failure CRF) is meant the clinical syndrome that renal function injury occurred due to constitutional or the Secondary cases chronic renal illness a series of symptoms and metabolism disorder are formed in chronic renal failure.It is generally acknowledged that its nephropathy is the potential sexual development that carries out, mostly be irreversible, and can be in a certain stage of the course of disease and to carry out sexual development and increasing the weight of.Its state of an illness is complicated and changeable, treat thorny, serious harm human beings'health and life, according to statistics, the annual morbidity of domestic CRF is 1,000,000/50-100 of nature crowd.In recent years, a large amount of tcm clinical practice data show that damp and hot have confidential relation with generation, development, treatment and prognosis nephropathy, and its importance is only second to syndrome of blood stasis.Therefore, eliminating damp-heat also becomes one of main method of the various nephropathys of treatment gradually.The reason of nephropathy being attacked by dampness thermosetting, extremely complicated, due to the existing diseases caused by exogenous pathogenic factor, also have damp and hot endogenously, also have reasons such as inside and outside combined pathogens and medicine diet.As seen, how CRF being carried out early prevention and treatment, and delay the disease progression of CRF, reduce uremic sickness rate, delay the time that CRF enters ESRD, is the important topic that the nephropathy researcher faces.
Doctor trained in Western medicine mainly is an integrated therapeutic at this disease Therapeutic Method, controls various risk factors, takes some symptomatic treatments simultaneously.In recent years, cost is low, side effect is little because Chinese medicine has, and particularly the characteristics such as whole opsonic action of treatment by Chinese herbs obtain the acceptance of extensive patients, and cause industry scholar's great attention.
Summary of the invention
The purpose of this invention is to provide a kind of medicinal composition for the treatment of chronic kidney hypofunction, be specifically related to a kind of Chinese medicine medicinal composition for the treatment of insufficiency of the spleen damp-heat type chronic renal failure, this medicinal composition is easy to use, with low cost, good effect.
The traditional Chinese medical science thinks, damp and hot is by damp and pathogenic heat a kind of paathogenic factor of forming of knot mutually, belongs to that the six climate exopathogens exopathogen closes and for it.In general damp and hot is not a kind of independently disease, but what make a general reference that all cause by damp and hot heresy is damp syndrome, is again heat syndrome, shows as dual syndrome.Yet damp and hot not exclusively is to be caused by exopathogen, but also due to the internal injury, damp has the branch of exogenous damp and endogenous dampness, external damp often has the strongly fragrant and process of heat-transformation, and the formation of endogenous dampness is many by spleen and stomach function mistake department, causes water liquid fortuneization obstacle and takes place, thus, water is wet is the basis of damp and hot generation.
The reason of nephropathy being attacked by dampness thermosetting, extremely complicated, due to the existing diseases caused by exogenous pathogenic factor, also have damp and hot endogenously, also have reasons such as inside and outside combined pathogens and medicine diet, all can produce damp-heat syndrome.Discuss according to ancient Chinese medicine doctor, in conjunction with modern clinical analysis, damp and hot generation probably has following several factor: (1), the inhabitation part dampness of a low-lying land, or paddle in spite of the rain, invade in the wet gas of water, or eating and drinking without temperance usually, wet accumulate in, dysfunction of the spleen in transportation, the strongly fragrant heat-transformation of a specified duration of damp forms damp and hot.(2), overstrain, damage temper adds hungryly full variable, causes the temper loss, gives birth in water is wet, and is strongly fragrant and heat-transformation leads to damp and hot.(3), plain body is weakened body resistance, and is or weak after being ill, feels the heresy of wind heat again, exopathogen and endogenous dampness are harmonious, and be strongly fragrant and heat-transformation also becomes damp and hot.
Though chronic kidney hypofunction is sick originally at kidney, because taste and kidney are closely related, with and main heresy of holding concurrently folder card turbid damp show as the taste lifting more and lack of proper care, so most of cases have burnt pathological changes in poor appetite, the nausea,vomiting,diarrhea etc., and the weight of gastrointestinal symptom changes consistent basically with the height that renal function is damaged degree and blood urea nitrogen numerical value.Say in " the Ling Shu Miraculous Pivot or Divine Axis mouth is asked a piece of writing ": " deficiency of QI in middle-JIAO, urinating just becomes for it." promptly disclosed the relation of taste and nephropathy.This shows, insufficiency of the spleenly damp and hotly in the pathogenic process of chronic renal failure, occupy important status.
Medicinal composition of the present invention is primarily aimed at the insufficiency of the spleen damp and hot pathogenesis of chronic kidney hypofunction, has established invigorating the spleen and benefiting QI, the rule of treatment of clearing away heat and eliminating dampness.Adopt Radix Codonopsis, the Radix Astragali, YIN-fire falls in invigorating the spleen and benefiting QI; The relieving constipation of Radix Et Rhizoma Rhei clearing away damp-heat, assistant is played invigorating the spleen and benefiting QI altogether with Rhizoma Atractylodis, Fructus Tsaoko dampness, and the merit of clearing away heat and eliminating dampness, principal indication show as the patient of syndrome of dampness-heat due to spleen deficiency type for the early metaphase chronic kidney hypofunction.
Chinese medicine complex of the present invention is through modern pharmacological research wherein: Radix Codonopsis contains saccharide, volatile oil, glycoside alkaloid, aminoacid and inorganic elements etc., have human body immunity improving power, blood pressure lowering, anticoagulant and effects such as reduction low density lipoprotein, LDL, triacylglycerol, can treat hypertension, hyperlipidemia, suppress thrombosis; The Radix Astragali contains flavone compound and various trace elements, has immunologic function, diuresis and the hypotensive effect of adjusting, can increase effects such as immunity of organisms and cardiac function protecting; Rhizoma Atractylodis contain volatile oil, include atractylone, hinesol etc., intestinal tube there are dual regulation, blood vessel dilating effect, antioxidation and immunoregulation effect, can treat gastrointestinal dysfunction, come protective tissue cellularity and function thereof by reducing lipid peroxidation; Fructus Tsaoko contains Fructus Tsaoko volatile oil and various trace elements, has the inhibition gastrointestinal motility, and effects such as diuresis and antiinflammatory, antibiotic, analgesic, analgesia can be treated Deficiency and coldness of spleen and stomach regurgitation vomiting; Rhizoma Coptidis contains multiple alkaloids such as coptisine, little bavin alkali, has inflammation-inhibiting reaction, blood pressure lowering, falls ester, blood sugar reducing function, can treat gastrointestinal dysfunction and hypertension, hyperlipemia etc.; Radix Et Rhizoma Rhei contains anthraquinone derivative, has to rush down down and effects such as antiinflammatory, infection, can treat renal failure and the gastrointestinal peristalsis digestive functional disturbance due to reducing etc.
Medicinal composition of the present invention is made (every pair of Chinese medicine) by the following weight Chinese medicinal raw materials: Radix Codonopsis 5-30 gram, Radix Astragali 5-45 gram, Fructus Tsaoko 3-20 gram, Rhizoma Atractylodis 5-30 gram, Rhizoma Coptidis 3-12 gram, Radix et Rhizoma Rhei (processed) 3-30 gram.
The preferred weight proportioning of medicinal composition of the present invention is: Radix Codonopsis 15 grams, Radix Astragali 15 grams, Fructus Tsaoko 6 grams, Rhizoma Atractylodis 10 grams, Rhizoma Coptidis 3 grams, Radix et Rhizoma Rhei (processed) 9 grams.
Medicinal composition of the present invention also can adopt Radix Pseudostellariae 5-30 gram to substitute the Radix Codonopsis invigorating the spleen and benefiting QI, Rhizoma Atractylodis Macrocephalae 10-45 gram substitutes Radix Astragali invigoration spleen qi, Magnolia officinalis Rehd. et wils. 5-30 gram substitutes Rhizoma Atractylodis dampness, Fructus Amomi gram 3-12 substitutes the Fructus Tsaoko removing dampness, Semen Plantaginis 10-45 gram substitutes Rhizoma Coptidis 3-12 gram, and Radix Et Rhizoma Rhei gram 3-15 gram substitutes Radix et Rhizoma Rhei (processed) 3-30 gram clearing away heat-damp and promoting diuresis.
Fried by following method: as to adopt ceramic earth pot or enamel enamelware pot, get the raw material of Chinese medicine of required weight, use cold water soak 30 minutes before frying in shallow oil, the water yield slightly exceeds the medicine one-inch, and the then corresponding minimizing of water of two juice is fried in shallow oil for a long time with slow fire, juice was fried in shallow oil 25 minutes, two juice were fried in shallow oil 15-20 minute, and head, two juice mix, and divide and take for 2-3 time, each 100ml-150ml, children's reduces by half, and Semen Plantaginis is decocted a drug wrapped with gauze in the medicine, and Radix Et Rhizoma Rhei need head is fried in shallow oil to finish and put in preceding 10 minutes.
The present invention confirms to have reduction serum creatinine, blood urea nitrogen, 24 hours quantitative, rising glomerular filtration rates (GFR) of albuminuria through clinical and zoopery, improve renal function, blood fat reducing, improve the SOD vigor, remove oxygen-derived free radicals, regulate the function of cellular immunization, influence the CRF cytokine-expressing and delay renal fibrosis, regulate the secretion of gut hormone and cytokine and improve the clinical symptoms of the insufficiency of the spleen damp-heat syndrome of chronic kidney hypofunction patient, regulate effects such as nephridial tissue aquaporin.
The specific embodiment
Embodiment 1
Adopt following weight Chinese medicinal raw materials (every pair of Chinese medicine): Radix Codonopsis 5 grams, Radix Astragali 5 grams, Fructus Tsaoko 3 grams, Rhizoma Atractylodis 5 grams, Rhizoma Coptidis 3 grams, Radix et Rhizoma Rhei (processed) 3 grams.Fried by following method: with the ceramic earth pot, the enamel enamelware pot is good.Use cold water soak 30 minutes before frying in shallow oil, the water yield slightly exceeds the medicine one-inch, the then corresponding minimizing of water of two juice.Fry in shallow oil for a long time with slow fire, a juice was fried in shallow oil 25 minutes, and two juice were fried in shallow oil 15-20 minute.Head, two juice mix, and divide and take for 2-3 time, each 100ml-150ml, and children's reduces by half.The Semen Plantaginis need be decocted a drug wrapped with gauze in the medicine, and Radix Et Rhizoma Rhei need head is fried in shallow oil to finish and put in preceding 10 minutes.
Also can adopt the Chinese medicine alternative materials preparation of following weight proportioning: Radix Pseudostellariae 5 grams, the Rhizoma Atractylodis Macrocephalae 10 grams, Magnolia officinalis Rehd. et wils. 5 grams, Fructus Amomi gram 3, Semen Plantaginis 10 grams, Radix Et Rhizoma Rhei 3 grams.
Embodiment 2
Adopt following weight Chinese medicinal raw materials (every pair of Chinese medicine): Radix Codonopsis 30 grams, Radix Astragali 45 grams, Fructus Tsaoko 20 grams, Rhizoma Atractylodis 30 grams, Rhizoma Coptidis 12 grams, Radix et Rhizoma Rhei (processed) 30 grams.Fried by following method: with the ceramic earth pot, the enamel enamelware pot is good.Use cold water soak 30 minutes before frying in shallow oil, the water yield slightly exceeds the medicine one-inch, the then corresponding minimizing of water of two juice.Fry in shallow oil for a long time with slow fire, a juice was fried in shallow oil 25 minutes, and two juice were fried in shallow oil 15-20 minute.Head, two juice mix, and divide and take for 2-3 time, each 100ml-150ml, and children's reduces by half.The Semen Plantaginis need be decocted a drug wrapped with gauze in the medicine, and Radix Et Rhizoma Rhei need head is fried in shallow oil to finish and put in preceding 10 minutes.
Adopt the Chinese medicine alternative materials preparation of following weight proportioning: Radix Pseudostellariae 30 grams, the Rhizoma Atractylodis Macrocephalae 45 grams, Magnolia officinalis Rehd. et wils. 30 grams, Fructus Amomi gram 12, Semen Plantaginis 45 grams, Radix Et Rhizoma Rhei 15 grams.
Embodiment 3
Adopt following weight Chinese medicinal raw materials (every pair of Chinese medicine): Radix Codonopsis 15 grams, Radix Astragali 15 grams, Fructus Tsaoko 6 grams, Rhizoma Atractylodis 10 grams, Rhizoma Coptidis 3 grams, Radix et Rhizoma Rhei (processed) 9 grams.Fried by following method: with the ceramic earth pot, the enamel enamelware pot is good.Use cold water soak 30 minutes before frying in shallow oil, the water yield slightly exceeds the medicine one-inch, the then corresponding minimizing of water of two juice.Fry in shallow oil for a long time with slow fire, a juice was fried in shallow oil 25 minutes, and two juice were fried in shallow oil 15-20 minute.Head, two juice mix, and divide and take for 2-3 time, each 100ml-150ml, and children's reduces by half.The Semen Plantaginis need be decocted a drug wrapped with gauze in the medicine, and Radix Et Rhizoma Rhei need head is fried in shallow oil to finish and put in preceding 10 minutes.
Embodiment 4 zooperies
1, laboratory animal: 80 of male SD rats, body weight 200 ± 20 grams are provided by Shuguang Hospital's Experimental Animal Center.
The complex of the present invention of experiment medicine: embodiment 3, wherein every ml contains crude drug 1.9g, fosinopril (trade name: MENGNUO): execute expensive precious pharmaceutical Co. Ltd by Sino-U.S. Shanghai and produce.Pentobarbital sodium: provide by Shanghai chemical reagents corporation of Chinese Medicine group.The high glucose and high fat feedstuff: add 10% Adeps Sus domestica, 10% Oleum Glycines and 10% sucrose on the basis of normal diet, heat energy content is 21.8kj/kg (normal diet heat energy content is 14.6kj/kg).
Experiment reagent: motilin, gastrin and interleukin-6, interleukin-6 receptor agents box are respectively available from the Fu Rui of Beijing bio-engineering corporation and Senxiong Science ﹠ Technology Industry Co., Ltd., Shanghai.Tumor necrosis factor-alpha (ratTNF-α) ELISA test kit, U.S. TPI company product.Nephridial tissue MDA, SOD, NEEA test kit build up bio-engineering research by poly-Lik-Sang thing engineering in medicine institute in Nanjing and Nanjing and are provided.Nephridial tissue oxidized low density lipoprotein (OX-LDL), aquaporin: OX-LDL antibody is available from U.S. Santa Cruz company, and aquaporin 2 antibody is available from Wuhan doctor's moral biotech company, and Envision reagent (R) is available from DaKo company.The erythrocyte C3b receptor spends bad rate (RCRR), erythrocyte immune complex rosette rate (RICR) zymosan reagent to be provided by the Shanghai Changhai Hospital epi chamber, and concentration is 1*108/ml.Renal cortex TGF-β 1 gene expression test kit is provided by Shanghai lottery industry Bioisystech Co., Ltd.
2. grouping and modeling: 80 rats are divided into 8 of normal group at random, 72 of modeling groups.72 of modeling group rats are used Platt method and reference literature excision rat 5/6 nephridial tissue making chronic renal failure animal model, method is as follows: with 2% pentobarbital sodium intraperitoneal injection of anesthesia rat, then with ether induced anesthesia, rat is lain on the back, the lower limb intersection is fixed on the operating-table to expose kidney district, a left side, back, from making oblique foreign side otch apart from left ridge rib bone 1.5cm.Get kidney through posterior peritoneum, expose kidney, separate around the kidney behind the fat and kidney peplos, camber excises 2/3 renal tissue (mainly excising the cortex part), uses the gelfoam hemostasis by compression for a moment, drips several fibrinogen solutions or thrombin solution again, waits a moment, the left kidney of the residue that after no longer including active hemorrhage on the tangent plane, resets, sew up, the whole right kidney of week back excision, two operations is excised kidney about about 80% altogether.Serum creatinine (Scr) is measured in the rat tail vein blood sampling in 2 week backs, makes to touch group rat serum creatinine to be significantly higher than normal group be model success (P＜0.05).The rat of model success has 65, according to the rat serum creatinine value after the modelling success, be divided into 7 groups, test factually and design and produce three kinds of models: model I: promptly carry out 10 days normal feedstuff feedings after left kidney 2/3 excision, right then kidney ligation, continue normal feedstuff feeding and measure serum creatinine after 7 days, be divided into model and with complex of the present invention treatment according to the serum creatinine value.Be called B group (normal diet+cut kidney+normal diet model group), C group (normal diet+cut kidney+normal diet treatment group); Model II: promptly carry out 10 days normal diet feedings after left kidney 2/3 excision, right then kidney ligation, continue to give high lipid food (normal diet adds 10% Adeps Sus domestica, 10% Oleum Glycines, 10% sucrose) feeding and measure serum creatinine after 7 days, be divided into model and contrast treatment according to the serum creatinine value then with complex of the present invention and MENGNUO.Be called D group (normal diet+cut kidney+high lipid food model group), E group (normal diet+cut kidney+high lipid food treatment group), F group (normal diet+cut kidney+high lipid food matched group); Model III: promptly carry out 10 days high lipid food feedings after 2/3 excision of left kidney, right then kidney ligation continues the high lipid food feeding and measures serum creatinine after 7 days, is divided into model according to the serum creatinine value then and treats with complex of the present invention.Be called G group (continuing high glucose and high fat feedstuff model group) and H group (continuing high glucose and high fat feedstuff treatment group).Continuing the high lipid food feeding during above-mentioned three kinds of model experiments finishes until experiment.Animal freely drinks water, ingests, natural illumination, and room temperature is fed.
3. treatment
Complex of the present invention, and fosinopril (trade name: MENGNUO, Sino-U.S. executes in Shanghai expensive precious pharmaceutical Co. Ltd).Animal-use drug is 20 times of calculating of body weight for humans dosage proportionately, give corresponding Chinese medicine and western medicine respectively to the rat of different groups and irritate stomach.
Complex 0.3 gram/100 gram rats of the present invention, the treatment group is irritated stomach once a day with complex of the present invention.Each 2ml.Matched group restrains/100 rat oral gavages once a day with fosinopril 0.003, each 2ml, continuous 8 weeks.Normal group and model group ad lib and drinking-water.Rats are put to death in 8 week backs, put to death respectively to organize rat the previous day and put metabolic cage respectively and collect twenty-four-hour urine liquid.Pluck the eyeball blood sampling, detect index of correlation.Cut open simultaneously and get gastric tissue and do pathologic finding and ultrastructure inspection.
4. observation index
Adopt the routine biochemistry method to detect: blood urea nitrogen, creatinine, triglyceride, cholesterol, high density lipoprotein, low density lipoprotein, LDL, routine blood test, 24h urine protein quantitation;
Measure SOD in the kidney homogenate and adopt xanthine oxidase; MDA adopts the thiobarbituricacid method; Free fatty (FFA) adopts the cupferron algoscopy;
Hematogaster therbligs, gastrin adopt radio immunoassay, and interleukin-6, interleukin-6 receptor adopt the ABC-ELISA method to detect;
Erythrocyte C3b receptor rosette rate (RBC-C3bRR) and red blood cell adhesion immune complex rosette rate (RBC-ICR): adopt erythrocyte rapid and natural immune adherence yeast functional examination method, zymosan reagent is provided by the Shanghai Changhai Hospital epi chamber, and concentration is 1*10
8/ ml.Get citric acid anticoagulation 1ml, centrifugal, getting supernatant, to put another test tube stand-by, and erythrocyte is made into 1.25*10
7/ ml uses liquid.50ul blood plasma adds the 50ul yeast soln and adds the abundant mixing of 50ul red cell suspension and survey RBC-C3bRR fully, other gets the 50ul red cell suspension and adds the abundant mixing of 50ul yeast soln and survey RBC-ICR fully, put into 37 ℃ of water-baths respectively after 30 minutes, take out and add 25ul0.25% glutaraldehyde mixing smear gently routinely, dry up dyeing, counting, in conjunction with saccharomycetic erythrocyte more than 2 is 1 garland, calculates rosette rate.
Nephridial tissue oxidized low density lipoprotein (OX-LDL), aquaporin: the SABC method detects, OX-LDL antibody is available from U.S. Santa Cruz company, aquaporin 2 antibody is available from Wuhan doctor's moral biotech company, Envision reagent (R) is available from DaKo company, after the kidney of rats fixation of tissue, paraffin embedding, slice thickness 4um, routine dewaxes to water, PBS buffer (0.01mol/l, PH7.4) wash 3 times, each 3min takes out behind the immersion 20min in the 1% hydrogen peroxide liquid, and the PBS buffer is washed 3 times, each 3min, section is placed the 0.01mol/l citrate buffer solution, and microwave is repaired 15min, naturally cools to room temperature, the PBS buffer is washed 3 times, each 3min, 1% normal goats serum sealing 20min drips 1: 100 rabbit anti-Mus OX-LDL antibody and aquaporin 2 antibody 50ul respectively, and replace an anti-negative control of doing with PBS, spend the night, the PBS buffer is washed 3 times, each 3min, drip biotin labeled Envision reagent 50ul, 30min, 37 ℃, the PBS buffer is washed 3 times, each 3min, the DAB colour developing, washing, the haematoxylin lining dyes 30s, dry up the resin mounting.The result adopts the IMS cytological image analyses system of medical images inspection center of Fudan University to carry out semi-quantitative analysis, 3 visuals field of every specimen picked at random, calculate the positive area and the positive intensity of pigmented section in each visual field, last average with every group compares.
Renal cortex TGF-β
1Gene expression: adopt the RT-PCR method, test kit is provided by Shanghai lottery industry Bioisystech Co., Ltd.
5. statistical disposition: all measurement results are represented with x ± s, t check between the employing group.
The result shows:
1. complex of the present invention is fed the influence of CRF kidney of rats function, routine blood test, twenty-four-hour urine protein quantification to different diet
Began to measure serum creatinine, blood urea nitrogen, cholesterol and triglyceride on the 7th day in operation back for the second time, divide into groups, make and respectively organize the serum creatinine value before the experiment beginning and do not have significant difference according to the serum creatinine value.See Table 1
Respectively divide into groups before table 1, the experiment beginning renal function and bent fat situation
Group N BUN Scr TC TG
A organizes 8 8.79 ± 1.11 33.63 ± 2.07 1.35 ± 0.54 1.59 ± 0.33
B organizes 10 21.24 ± 5.54 57.8 ± 8.68 1.86 ± 0.24 0.30 ± 0.08
C organizes 10 20.94 ± 4.67 57.8 ± 8.22 1.81 ± 0.32 0.27 ± 0.11
D organizes 10 20.24 ± 6.16 62.3 ± 22.6 2.07 ± 0.52 0.53 ± 0.56
E organizes 10 19.55 ± 3.86 58.90 ± 12.42 1.91 ± 0.47 0.45 ± 0.45
F organizes 10 20.13 ± 4.08 58.3 ± 9.98 2.03 ± 0.25 0.29 ± 0.07
G organizes 7 15.00 ± 2.06# 60.71 ± 6.90 2.44 ± 0.20# 0.53 ± 0.09
H organizes 8 15.18 ± 2.54# 60.38 ± 8.02 2.24 ± 0.27#, 0.70 ± 0.19#
# and normal group be p＜0.05 relatively
After the grouping, each organizes serum creatinine and the relatively more equal difference of normal group remarkable (p＜0.05), but compare indifference between respectively organizing, continue high lipid food treatment group and continue the reduction of high lipid food model group blood urea nitrogen and all the other model group, cholesterol, triglyceride are respectively organized all than all the other and are obviously raise.
Treatment is measured renal function after January, observes the variation of respectively organizing serum creatinine, blood urea nitrogen value and sees Table 2.
The situation of renal function is respectively organized in table 2, experiment after January
Group N BUN Scr
A organizes 8 11.03 ± 0.79 51.88 ± 2.53
B organizes 9 19.64 ± 1.91#, 80.89 ± 10.37#
C organizes 8 19.09 ± 3.27#, 78.13 ± 13.66#
D organizes 9 21.44 ± 5.43#, 88.44 ± 16.50#
E organizes 9 16.74 ± 2.81# ☆, 69.78 ± 9.50# ※ ☆
F organizes 10 17.05 ± 3.97# ☆, 76.10 ± 23.15#
G organizes 7 23.64 ± 3.60#*, 90.29 ± 17.13#
H organizes 8 18.26 ± 3.93#, 76.75 ± 12.14#
The high lipid food matched group compared p＜0.05 after the high lipid food model group compared p＜0.01 ※ and cuts kidney after # and normal group compared p＜0.01 * and normally the feedstuff model group compares p＜0.05 ☆ and cuts kidney
Each model group creatinine, blood urea nitrogen have significant rising than normal group after January, and cutting high lipid food treatment group behind the kidney has decline than the serum creatinine of model group of the same race, illustrates to begin to have the effect that improves renal function.Continue high lipid food treatment group and begin that also the effect that reduces creatinine, blood urea nitrogen is arranged.
Table 3, complex of the present invention are fed CRF kidney of rats functions and albuminuria result (x ± s) to different diet
Group N BUN Scr 24h urine protein
A organizes 8 9.26 ± 0.37 35.38 ± 5.07 23.26 ± 4.44
B organizes 9 16.68 ± 3.14##, 61.14 ± 9.39##, 34.78 ± 8.13##
C organizes 8 15.14 ± 3.80 55.56 ± 7.47 24.70 ± 5.73**
D organizes 9 22.29 ± 4.60##*, 84.13 ± 23.44##, 43.94 ± 4.84##*
E organizes 9 18.5 ± 2.79 59.43 ± 8.16 ☆ 36.33 ± 6.76 ☆
F organizes 9 18.62 ± 5.44 62.78 ± 15.67 28.94 ± 6.80 ☆
G organizes 7 32.32 ± 10.80##, 132.83 ± 62.37##, 63.17 ± 14.66##
**※※ **※※ **※※
H organizes 6 18.59 ± 7.19 △ △, 72.88 ± 26.63 △ △, 38.77 ± 9.46 △ △
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.01 relatively
Each model group blood urea nitrogen, creatinine and 24h urine protein quantitation all were significantly higher than normal group (P＜0.05) when experiment finished, between three model group along with the increase of high fat high-carbonhydrate diet, blood urea nitrogen, creatinine and 24h urine protein quantitation are all on the rise, the degree and the high fat high-carbonhydrate diet that rise are proportionate, and remarkable significant difference is arranged, illustrate and give 5/6 nephrectomy rat high fat high-carbonhydrate diet, its 24 hours protein quantifications and serum creatinine, blood urea nitrogen are significantly raise, thereby set up the CRF animal model of damp and hot pattern of syndrome.Normal feedstuff treatment group has the effect of remarkable reduction 24h urine protein quantitation than normal feedstuff model group.Cut high lipid food treatment group behind the kidney and can significantly suppress chronic kidney hypofunction and feed serum creatinine and 24h urine protein quantitation with the high-sugar-fat-diet rat, complex of the present invention has remarkable reduction and continues high lipid food model group serum creatinine, 24h urine protein quantitation and blood urea nitrogen effect (P＜0.01).The glad Puli of good fortune group has the effect that high lipid food model group 24h urine protein quantitation behind the kidney is cut in remarkable reduction, serum creatinine, blood urea nitrogen is also had the decline effect, but do not have the significance meaning on the statistics.
Table 4, each group experiment finish the situation of change of back routine blood test
Group N RBC HB
A organizes 8 7.82 ± 0.64 157.21 ± 11.94
B organizes 9 5.64 ± 0.87 118.00 ± 12.90
C organizes 8 5.18 ± 0.75 106.25 ± 13.11*
D organizes 9 5.56 ± 0.65 113.56 ± 10.90
E organizes 9 6.06 ± 0.46 124.33 ± 7.94 ☆
F organizes 9 6.42 ± 0.40 ☆, 127.67 ± 8.17 ☆
G organizes 7 6.56 ± 0.39*, 129.29 ± 6.32* ☆
H organizes 6 6.58 ± 0.34 127.83 ± 3.31
* the high lipid food model group compares p＜0.01 after comparing p＜0.05 ☆ and cut kidney with normal feedstuff model group
The result shows, continuing high lipid food model group RBC, HB has significant rising than normal feedstuff model group, illustrates that high nutrition has the improvement effect to anemia, cuts high lipid food treatment group and matched group behind the kidney than the be significantly improved function of HB of model group.
2. complex of the present invention is to the influence of the CRF rat fat of different diet nursings
Table 5 complex of the present invention is fed the result (x ± s mmol/L) of CRF rat fat to different protein diet
Group N TG TC HDL LDL
A organizes 8 1.56 ± 0.25 0.40 ± 0.07 0.96 ± 0.19 0.35 ± 0.07
B organizes 9 2.22 ± 0.59 0.66 ± 0.13 1.46 ± 0.46#, 0.54 ± 0.11#
C organizes 8 1.53 ± 0.31 0.40 ± 0.07 0.92 ± 0.24*, 0.34 ± 0.07*
D organizes 9 3.72 ± 0.99##**, 1.28 ± 0.39##*, 2.21 ± 0.72##**, 0.84 ± 0.21##
**
E organizes 9 2.09 ± 1.66 ± 0.84 1.39 ± 0.30 ±
0.72☆☆※※ 0.60☆☆※※ 0.23☆☆※※
F organizes 9 3.30 ± 0.62 1.28 ± 0.32 1.99 ± 0.40 0.73 ± 0.17
G organizes 7 3.56 ± 1.81##**, 1.65 ± 1.48##, 2.03 ± 0.72##*, 0.86 ± 0.50##
** **
H organizes 6 2.55 ± 0.40 △, 0.89 ± 0.17 △ 1.64 ± 0.24 0.54 ± 0.09 △ △
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The result shows: blood TG, the TC, LDL and the HDL that cut high lipid food model group and lasting high lipid food model group behind the kidney are apparently higher than normal group, and in the high lipid food model group TG, TC, LDL and HDL apparently higher than normal feedstuff model group (P＜0.05-0.01), illustrate that high fat high-carbonhydrate diet can increase the weight of the abnormalities of sugar/lipid metabolism of chronic kidney hypofunction rat; And HDL, the LDL of normal feedstuff model group are significantly higher than normal group (P＜0.05); Normal feedstuff treatment group has the effect of significant decline compared with the LDL in the normal feedstuff model group; Complex of the present invention not only after cutting kidney high lipid food group (except that triglyceride) still the effect of obvious inhibition cholesterol, triglyceride and low density lipoprotein, LDL is all arranged continuing the high lipid food group.And complex of the present invention cholesterol in the high lipid food group, low density lipoprotein, LDL curative effect after cutting kidney obviously are better than matched group.The glad Puli's group of good fortune only has the effect that reduces model group TG of the same race, LDL, but curative effect is not as good as complex group of the present invention.
3. the influence of the CRF rat stomach therbligs that complex of the present invention is fed different diet, gastrin, interleukin
Table 6 complex of the present invention is to the result of CRF rat stomach therbligs, gastrin, interleukin (x ± s)
Group N motilin gastrin interleukin-6 interleukin-6 receptor
A organizes 8 67.09 ± 4.36 17.31 ± 6.70 5.53 ± 2.38 7.40 ± 1.85
B organizes 9 97.63 ± 14.41#, 33.50 ± 14.52# 7.85 ± 2.39 9.18 ± 3.28
C organizes 8 80.68 ± 13.63 16.43 ± 8.98* 6.55 ± 2.83 8.44 ± 1.65
D organizes 9 114.04 ± 53.44#, 33.72 ± 16.62#, 9.05 ± 4.94## 8.42 ± 3.00
# #
E organizes 9 79.47 ± 14.46 ☆ 21.82 ± 14.25 5.41 ± 1.83 ☆ 7.71 ± 1.43
F organizes 9 90.83 ± 9.83 29.92 ± 12.07 7.75 ± 2.31 7.41 ± 2.01
G organizes 7 118.13 ± 49.53#, 52.27 ± 26.84#, 11.35 ± 3.30##* 9.40 ± 1.65
# #*
H organizes 6 84.51 ± 11.31 △, 30.93 ± 18.80 △, 6.58 ± 1.82 △ △ 8.22 ± 0.82
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The result shows: the hematogaster therbligs, gastrin, interleukin-6 of cutting high lipid food model group and lasting high lipid food model group behind the kidney are apparently higher than normal group, and hematogaster secretin, the interleukin-6 of lasting high lipid food model group are significantly higher than normal feedstuff model group (P＜0.05-0.01), illustrate that high fat high-carbonhydrate diet can increase the weight of the gastrointestinal disease of chronic kidney hypofunction rat; Complex of the present invention not only after cutting kidney the high lipid food group still the effect of obvious inhibition motilin, interleukin-6 is all arranged continuing the high lipid food group.And the effect (P＜0.05) of remarkable inhibition gastrin is arranged continuing high lipid food group complex of the present invention.The glad Puli's group of good fortune has the effect that reduces model group motilin of the same race, gastrin, interleukin-6, but not statistically significant.
4. the CRF rat erythrocyte C that complex of the present invention is fed different diet
3The influence of b receptor rosette rate, erythrocyte immune complex rosette rate
The result of CRF rat RCRR, RICR that table 7, complex of the present invention are fed different diet (x ± s)
Group N RCRR RICR
A organizes 8 30.5 ± 5.22 4.63 ± 2.00
B organizes 9 16.00 ± 3.87##, 10.78 ± 2.89##
C organizes 8 27.38 ± 4.24**, 4.75 ± 1.03**
D organizes 9 11.06 ± 3.31##**, 17.94 ± 2.95##**
E organizes 9 18.33 ± 3.30 ☆ ☆, 7.00 ± 1.18 ☆ ☆
F organizes 9 17.56 ± 4.22 ☆ ☆ 12.11 ± 3.55
G organizes 7 6.50 ± 1.58##** ☆ ☆, 28.50 ± 3.56##** ☆ ☆
H organizes 6 12.92 ± 1.32 △ △, 12.92 ± 2.94 △ △
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The result shows: normal feedstuff model group, cut behind the kidney erythrocyte C3b receptor rosette rate of high lipid food model group and lasting high lipid food model group be starkly lower than with the erythrocyte immune complex rosette rate apparently higher than normal group, and cut behind the kidney blood RCRR of high lipid food model group and lasting high lipid food model group and significantly be lower than with RICR and be significantly higher than normal feedstuff model group (P＜0.05-0.01), and the high sugar of high fat is to erythrocyte C3b receptor rosette rate, the influence of erythrocyte immune complex rosette rate and the time of nursing are proportionate, illustrate that the immunologic function that high fat high-carbonhydrate diet can increase the weight of the chronic kidney hypofunction rat goes down, form weakened body resistance performance as the chronic kidney hypofunction patient; Complex of the present invention all is significantly increased RCRR and suppresses the effect (P＜0.01) of RICR in three kinds of modeling methods.The glad Puli of good fortune group has remarkable rising to cut the effect (P＜0.01) of the RCRR of high lipid food rat model behind the kidney, but RICR is had the effect not statistically significant of reduction.
5. complex of the present invention is to the CRF kidney of rats tissue oxidizing low density lipoprotein, LDL of different diet nursings and the influence of transforming growth factor-beta 1
The CRF kidney of rats that table 8, complex of the present invention are fed different diet is organized ox-LDL, TGF-β 1 (x ± s)
Group OxLDL ELISA TGF-β 1
Positive reflection area positive expression intensity
A organizes 8 14246.11 ± 5021.13 10.44 ± 1.42 0.24 ± 0.03
B organizes 9 31014.33 ± 4478.36##, 13.33 ± 1.00##, 0.67 ± 0.42##
C organizes 8 28377.22 ± 6629.15 13.22 ± 1.20 0.42 ± 0.11**
D organizes 9 38228.00 ± 8661.67##*, 14.11 ± 1.62##, 1.00 ± 0.00##**
E organize 9 22799.11 ± 6134.00 ☆ ☆, 11.67 ± 0.71 ☆ ☆ 0.49 ±
0.22☆☆※※
F organizes 9 26456.56 ± 7295.33 ☆ ☆, 11.67 ± 0.71 ☆ ☆ 0.51 ± 0.29
G organizes 7 46919.56 ± 7434.37##, 14.00 ± 1.41##, 1.04 ± 0.41##**
**☆☆
H organizes 6 32191.00 ± 7724.47 △ △, 12.90 ± 1.05 △, 0.36 ± 0.22 △ △
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The result shows: normal feedstuff model group, cut the nephridial tissue OxLDL ELISA of high lipid food model group and lasting high lipid food model group behind the kidney and transforming growth factor-beta 1 apparently higher than normal group, and cut the positive reflection area of the OxLDL ELISA of high lipid food model group and lasting high lipid food model group behind the kidney and transforming growth factor-beta 1 and be significantly higher than normal feedstuff model group (P＜0.05-0.01), illustrate that high fat high-carbonhydrate diet can increase the weight of abnormalities of sugar/lipid metabolism and the inflammation performance of chronic kidney hypofunction rat, quickens the formation of chronic kidney hypofunction glomerular sclerosis and renal tubules interstitial fibrosis; Complex of the present invention and Fu Xin Puli have the positive reflection area of obvious reduction OxLDL ELISA and the effect (P＜0.01) of positive expression intensity to high lipid food rat model after cutting kidney.Complex group of the present invention has the effect of obvious reduction transforming growth factor-beta 1 and is better than matched group high lipid food rat model after cutting kidney; Complex of the present invention has the effect (P＜0.01) of the positive reflection area, positive expression intensity and the transforming growth factor-beta 1 of remarkable reduction OxLDL ELISA in continuing the high lipid food model.
6. complex of the present invention is to the CRF kidney of rats tissue oxidizing antioxidant system of different diet nursings and the influence of free fatty
CRF kidney of rats tissue SOD, MDA and the NEEA that table 9, complex of the present invention are fed different diet (x ± s)
Group N SOD MDA NEFA
A organizes 8 409.94 ± 50.28 12.90 ± 3.11 19.95 ± 15.64
B organizes 9 226.51 ± 67.73#, 17.18 ± 3.86##, 64.93 ± 45.94##
#
C organizes 8 351.10 ± 91.45*, 12.85 ± 2.97**, 24.11 ± 16.39**
D organizes 9 118.37 ± 50.39#, 21.85 ± 3.47##**, 122.66 ± 49.38##**
#*
E organizes 9 311.45 ± 16.59 ± 2.20 ☆ ☆, 26.63 ± 13.23 ☆ ☆
171.64☆☆
F organizes 9 232.43 ± 99.93 ☆ 20.07 ± 2.52 33.21 ± 20.88 ☆ ☆
G organizes 7 68.08 ± 46.60##, 27.66 ± 1.84##, 162.33 ± 47.39##
** **☆☆ **☆
H organizes 6 216.43 ± 21.68 ± 3.40 △ △, 38.65 ± 17.10 △ △
181.25△△
# and normal group be p＜0.05 relatively; ## and normal group be p＜0.01 relatively
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; ※ ※ with cut behind the kidney relatively p＜0.01 of high lipid food matched group
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The result shows: normal feedstuff model group, cut that the nephridial tissue SOD of high lipid food model group and lasting high lipid food model group is starkly lower than behind the kidney, MDA and NEEA be apparently higher than normal group, and cut high lipid food model group and lasting high lipid food model group behind the kidney and compare the variation of SOD, MDA and NEEA and high fat high-carbonhydrate diet time with normal feedstuff model group and be tangible dependency (P＜0.05-0.01) illustrates that high fat high-carbonhydrate diet can increase the weight of the unusual of the lipid metabolism of chronic kidney hypofunction rat and oxidation antioxidation system; Complex of the present invention and Fu Xin Puli can obviously improve SOD that cuts high lipid food rat model behind the kidney and the effect (P＜0.01) that reduces NEEA.Complex group of the present invention has the effect of obvious reduction MDA to cutting high lipid food rat model behind the kidney; Be significantly increased SOD and reduce the effect (P＜0.01) of MDA and NEEA of complex of the present invention in continuing the high lipid food model.
7. CRF kidney of rats tissue water channel protein (AQP) influence that complex of the present invention is fed different diet
The CRF kidney of rats that table 10, complex of the present invention are fed different diet is organized AQP (x ± s)
Group N aquaporin
Sun is given birth to reflection area positive expression intensity
A organizes 8 22246.80 ± 7632.39 8.27 ± 1.53
B organizes 9 14569.47 ± 6986.06#, 5.07 ± 1.39#
C organizes 8 20827.93 ± 7424.58*, 7.87 ± 0.92*
D organizes 9 14982.07 ± 4548.83#, 5.87 ± 1.13#
E organizes 9 21354.0 ± 4149.98 ☆ ☆, 8.30 ± 0.82 ☆ ☆ ※
F organizes 9 19921.2 ± 5009.74 ☆, 7.27 ± 0.80 ☆ ☆
G organizes 7 12078.8 ± 4447.31#, 5.80 ± 1.37#
H organizes 6 18039.87 ± 4313.52 △, 7.13 ± 1.51 △
# and normal group relatively p＜0.01 * compare p＜0.01 with normal feedstuff model group
* compare p＜0.05 with normal feedstuff model group; * compares p＜0.01 with normal feedstuff model group
☆ with cut behind the kidney relatively p＜0.05 of high lipid food model group; ☆ ☆ with cut behind the kidney relatively p＜0.01 of high lipid food model group;
※ with cut behind the kidney relatively p＜0.05 of high lipid food matched group; △ and lasting high lipid food model group be p＜0.01 relatively
△ and lasting high lipid food model group be p＜0.05 relatively; △ △ and lasting high lipid food model group be p＜0.05 relatively
The aquaporin of comparing the nephridial tissue of three kinds of model group with normal kidney tissue all has decline in various degree, and descend the most remarkable to continue the high lipid food model group, illustrate with lipid the influence of renal function is obviously added the metabolic disorder of heavy water liquid, by each group of complex treatment of the present invention back rising is in various degree arranged all, statistics all has the highly significant meaning.
8. different high fat diets to CRF rat stomach histopathology result of variations relatively
Normal group stomach texture is normal down for light microscopic (HE), the mucous layer marshalling, and body of gland abundance in the mucous layer, lamina propria is lax under the mucosa, does not have the fibrosis hypertrophy, and the flesh layer is normal; Gastric mucosa top layer and fundic gland are normal under the Electronic Speculum, chief cell, Interstitial cell and mucous neck cell's structural integrity, MG and zymogen granule abrim, no inflammatory cell infiltration.
Normal feedstuff model group (B group): see the gastric mucosa attenuation under the light microscopic, body of gland reduces, organelle degeneration under the Electronic Speculum, there is lamellar body to occur, reticulum dilatation, nuclear membrane and endoplasmic reticulum connect together, the enlargement of pipe of parietal cell endocrine, it is irregular to distribute, the expansion of chief cell nuclear membrane, blood vessel blockage (being full of erythrocyte).
Mucosa thickens under normal feedstuff model treatment group (C group) light microscopic, and body of gland increases, and the nuclear membrane expansion alleviates under the Electronic Speculum, chief cell nuclear is normal substantially, and nuclear membrane is normal, and zymogen granule is complete, endoplasmic reticulum is slightly expanded, and blood vessel blockage alleviates, and erythrocyte reduces than pathologic group in the blood vessel.
Cut behind the kidney the lax cavity that forms of gastric mucosa under high lipid food model group (D group) light microscopic, body of gland reduces, and Electronic Speculum lower wall emiocytosis pipe reduces, and is undeveloped, secretory function is not vigorous, and the mucomembranous surface epithelial cell is impaired, and nuclear limit collection solidifies, reticulum dilatation, fiber increases, and has a large amount of fibers in the matter.
Cut behind the kidney that mucosa obviously thickens under high lipid food model treatment group (E group) light microscopic, body of gland increases, and the chief cell form is normal under the Electronic Speculum, Interstitial cell is normal, and the secretory cell morphological function is normal, and the secretion function pipeline is in the secretory phase, rete malpighii is normal, and interstitial fibers is less, the blood vessel mediation.
Cut behind the kidney that mucosa thickens under high lipid food model control group (F group) light microscopic, body of gland increases slightly, the cell surface rete malpighii is complete under the Electronic Speculum, visible microvillus, and secretory function is vigorous, the fundic gland blood vessel blockage, the broadening of gland C intercellular substance, pillar cells nuclear limit is moved, and form is irregular, parietal cell is roughly normal, and intercellular substance has small amount of fibers.
Mucosa forms fibrosis down under continuous high lipid food model group (G group) light microscopic, and body of gland reduces the mucous layer attenuation, forms the space, body of gland atrophy under the Electronic Speculum, undifferentiated cell is many, and blood vessel slightly stops up, the cytopathy necrosis, the myxocyte function is not good enough, and granule is roughly normal, the parietal cell nuclear degeneration is dwindled, the nuclear membrane expansion, and secretory function is not vigorous, between matter increase cell irregular arrangement, fiber aggregate bunchy in the matter, fibroplasia, the bottom is irregular.
Mucosa obviously thickens under lasting high lipid food model treatment group (H group) light microscopic, body of gland increases, fiber disappears, Electronic Speculum lower wall emiocytosis function is vigorous, the expansion of parietal cell secretion pipeline, and parietal cell mucous neck cell basal cell does not break up (normally), the nuclear membrane expansion alleviates, zymogen granule is complete, reticulum dilatation, and function is vigorous.
Embodiment 5 in vitro studies experiment
1, cell: pig near-end renal cells pearl (LLC-PK) (Hangzhou Chinese Medicinal Hospital nephropathy center)
2, normal, toxin and pastille serum preparation: the normal group in the zoopery, continue 2h behind high glucose and high fat model group and the complex treatment group rat medicine feed of the present invention, anesthesia, aseptic abdominal aortic blood, centrifugal, separation of serum, 56 ℃ of deactivations 20 minutes, bacteriological filtration.
Used key instrument:
The vertical clean bench of SW-CJ-1F (Purifying Equipment Co., Ltd., Suzhou), U.S. SHELLAB2306-2CO
2Incubator, the OLYNPAS inverted phase contrast microscope, the GL-20G-II High speed refrigerated centrifuge, culture bottle and culture plate (the cell biological company of growing directly from seeds), pcr gene amplification instrument (PE company 9600 types), computer aided video system (FR-2000 of Shanhai Furi Science and Technology Co., Ltd. type), primer is synthetic by Shanghai lottery industry Bioisystech Co., Ltd.
Main biochemical reagents
DMEM/F12 cell culture fluid: contain Hepes (1M) 7.5ml, 7.5%NaHco among the DMEM/F12 culture fluid 500ml
37.5ml, two anti-(green grass or young crops/streptomycins) each 50,000 u, sodium glutamate (200mM) 10ml, hyclone (10%); Reagent is provided by Hangzhou lucky promise biological medicine technology company limited;
Digestive system: with the 0.1MPBS preparation, concentration is 0.25% trypsin and 0.02%EDTA, and reagent is provided by the magnificent company in Shanghai;
Trizol extracting solution: provide by GIBCO BRC company;
The RT-PCR related reagent:
M-MuLV(200U/ul) (Gibco)
Taq polymerase(5U/ul) (Gibco)
RNAsin(40U/ul) (promaga)
DNTP (each 10mM) (lottery industry biotech company)
DNA marker (each 100bp gives birth to worker biotech company)
3, method
Cell culture: the LLC-PK cell strain that recovery obtains and in the DMEM/F12 culture fluid, cultivating go down to posterity (37 ℃, 5%CO
2), 5-10 is used for experiment for cell.With above-mentioned cell seeding in 50cm
2In culture bottle and 48 well culture plates, treat that cell covers with 70-80% after, cultivate 24h with serum-free medium and make cell be synchronized with G
0Phase, grouping then gives corresponding culture fluid and cultivates.
Grouping: carry out dosage respectively and rely on (containing 5% and 10% serum respectively) and time (8h and 24h) dependence research.Normal group: add variable concentrations in the culture fluid and continue high-sugar-fat-diet model group and normal rat serum; Treatment group: add variable concentrations in the culture fluid and continue high-sugar-fat-diet model group and complex treatment group rat blood serum of the present invention; Model group: add variable concentrations in the culture fluid and add tumor necrosis factor-alpha (TNF-α) or adopt lasting high-sugar-fat-diet model group serum, when 8h and 24h, digest and collecting cell respectively with Digestive system, add 1mlPBS with the cell mixing, centrifugal and collecting cell is put into liquid nitrogen in order to extracting RNA.Each experimental group of cell on the culture plate is established 6 multiple holes, gets supernatant TNF-α to be measured and FN.
Observation index:
The detection of supernatant TNF-α, FN: the ELISA method, tumor necrosis factor-alpha (rat TNF-α) ELISA test kit (lot number: 0321HE), U.S. TPI company product
Cell TGF-β
1MRNA: adopt the RT-PCR method,
(1) extracting of total RNA: cell 10
6-10
7Individual, add 1ml Trizol liquid, blow and beat mixing repeatedly with the rifle head, 22 ℃, leave standstill 5min, add chloroform 0.2ml, put upside down 15s, 22 ℃, leave standstill 3min, centrifugal, get supernatant 0.5ml, add the 0.5ml isopropyl alcohol, mixing, 22 ℃, leave standstill 10min, centrifugal, abandon liquid, add 4 ℃ of 75% ethanol of 1ml, centrifugal, abandon liquid, vacuum drying 5min is with the dissolving of 25ul DEPC treating water ,-70 ℃ of preservations.
(2) synthetic primer: according to the pig TGF-beta gene sequence of having reported, primer is synthetic by Shanghai lottery industry Bioisystech Co., Ltd.
(3) reverse transcription (RT) reaction condition and reaction system are according to a conventional method.
(4) the pcr amplification reaction system according to a conventional method.
(5) electrophoresis and analysis: after getting PCR product 20ul and sample-loading buffer 5ul mixing, be splined in 1.6% the agarose gel, wherein a hole adds DNA marker, 80V voltage, electrophoresis 1 hour.The gel analysis systematic observation is taken pictures, and the machine image analysis system carries out data analysis as calculated at last.With renal cells TGF-β
1The result of mRNA and β-actin mRNA carries out gray scale scanning with the computer PS, draws the gray value of these gene bands.Again the average of the ratio of their gray value and respective sample β-actin mRNA gray value as the relative amount of transcribing of this gene in this group sample.
Statistical method: cell TGF-β
1MRNA result gets average; Cell conditioned medium liquid FN result add up with SPSS software, and data are represented with mean ± standard deviation, relatively adopt one factor analysis of variance between group.
Embodiment 6 clinical trials
All cases derive from June, 2003 to 2004 year December in the patient of Shuguang Hospital's Urology Department outpatient service, ward diagnosis and treatment.
Diagnostic criteria is according to chronic kidney hypofunction (CHINESE JOURNAL OF INTERNAL MEDICINE editorial board nephropathy special interest group peaceful summary of a forum in Anhui in 1992) by stages, Chinese medical discrimination typing standard (All-China Association of Traditional Chinese Medicine's traditional Chinese medical science nephropathy academic conference for the third time 1999).
Early metaphase chronic renal failure diagnostic criteria: chronic nephritis or other nephropathy medical histories are arranged, and serum creatinine (Scr) slightly increases (Scr 115-442 μ mol/L) grade scale glomerular filtration rate (GFR) 15-60ml/min/1.73m according to the chronic nephropathy renal damage (CKD) of K/DOQI recommendation
2
Meet early metaphase chronic renal failure diagnosis; Serum creatinine is at 115-442umol/L; Glomerular filtration rate 15-60ml/min; The twenty-four-hour urine protein quantification is greater than 0.2 gram; Meet above Chinese medical discrimination typing and be the deficiency-weakness of spleen-QI damp-heat type person that holds concurrently; Age is in 18-80 year; Do not accept dialysis treatment; Allly meet above-mentioned standard person, include the observation case in.
Do not meet the above-mentioned standard of including in; Or with renal artery stenosis, or a large amount of albuminuria used hormone, immunosuppressant in nearly January, or merge have the inclination, serious primary diseases such as brain, liver and hemopoietic system, allergic constitution or to multiple drug allergy person, gestation or women breast-feeding their children can't partners (as the psychotic); Do not finish the infull person of treatment or data; Capable dialysis replacement therapy person; Get rid of.
Reject the case standard: do not meet and include standard person in; To this medicine allergy sufferers; Not medication in accordance with regulations; Patient's compliance is poor; Can't judge that curative effect or data are not congruent affects the treatment or safety judgement person.
Take parallel control method at random.Produce random number (1-120) with SAS software, produce corresponding random number, comprise 20% the case that comes off.Enter the clinical observation sequencing according to the patient, select corresponding random number, be divided into treatment group and matched group and observe.
Have 110 routine patients and receive clinical observation, wherein 1 example is not finished treatment, and 3 routine data are incomplete, finally have 106 examples and carry out analysis of cases, and wherein 53 examples are organized in matched group 53 examples, treatment.
53 examples are organized in treatment: male's 28 examples, and women's 25 examples, in age 27-77 year (average 58 years old), wherein protopathy is chronic glomerulonephritis 44 examples, metabolic arthritis nephropathy 1 example, diabetic nephropathy 5 examples, hypertensive renal arteriosclerosis 2 examples, polycystic kidney 1 example.
Matched group 53 examples: male's 26 examples, women's 27 examples, age 32-75 year (average 57.5 years old), wherein protopathy is chronic glomerulonephritis 42 examples, metabolic arthritis nephropathy 3 examples, ischemic nephropathy 2 examples, medicine renal damage 1 example, diabetic nephropathy 4 examples, hypertensive renal arteriosclerosis 1 example.
The above-mentioned relatively there was no significant difference of physical data of respectively organizing.
Therapeutic Method:
Each is organized the patient and all gives general processing earlier, alleviate all the other various factors of bringing out and increasing the weight of renal failure, as control infection, heart failure, correct anemia, Water-Electrolyte disorder, acid base imbalance etc., controlling blood pressure is based on calcium ion antagonist or central depressor.
1, combination of Chinese and Western medicine group is treated 53 examples;
Reversible aggravation factor is dispeled in protopathy treatment (as the nephritis of diabetes, systemic lupus erythematosus (sle), activeness, chronic pyelonephritis etc.);
Diet Therapy: the supply of protein and essential amino acids: the high-quality low protein diet, be generally 0.5-0.6g/kg, an amount of saccharide, fat are to guarantee enough heats, low-phosphorous diet.Suitable vitamin and trace element give.During anasarca, the sodium amount should be limited in about 3g every day;
The risk factor treatment:
The imbalance of correction water balance; Correct the hyperpotassemia potassium lower resin; Correct the metabolic acidosis sodium bicarbonate; Correct low calcium and hyperphosphatemia with Rocaltrol etc.; Correct the renal anemia erythropoietin; Correct renal hypertension with Angiotensin-Converting or acceptor inhibitor treatment, as MENGNUO, losartan etc.; Infection is selected antibiotics for use according to the state of an illness; The anticoagulant ticlid see ticlopidine; Blood lipid regulation SHUJIANGZHI and fenofibrate capsules etc.
The embodiment of the invention 3 complex treatment: instructions about how to take medicine: tip of the day, divide the secondary decoction.
2, the Western medicine group is treated 53 examples:
Doctor trained in Western medicine protopathy, modern nutrition and risk factor Therapeutic Method are the same.
The course of treatment: 30 days is a course of treatment, observes 2 courses of treatment.
Symptom grading standard is divided into level Four according to the Stanghellini standard by the symptom weight.
The tcm syndrome efficacy assessment standard:
Total mark * 100% before therapeutic effect of syndrome rate=(total mark before the treatment-treatment back total mark)/treatment
Clinic control: treatment back therapeutic effect of syndrome rate 〉=90%
Produce effects: treatment back therapeutic effect of syndrome rate 〉=70%,＜90%
Effectively: treatment back therapeutic effect of syndrome rate 〉=30%,＜70%
Invalid: treatment back therapeutic effect of syndrome rate＜30%
Clinical laboratory's curative effect determinate standard is with reference to " new Chinese medicine clinical research guideline ".
All cases all detect following index before treatment and after the treatment:
1) clinical symptoms and integration
According to every primary symptom of Chinese medical discrimination typing, inferior disease and picture of the tongue, pulse condition etc., observe before the patient treatment and the variation after treatment 2 courses of treatment, and the evaluation integration.
2) routine blood test and biochemical indicator
Serum creatinine (Scr), blood urea nitrogen (BUN), hematochrome (HGB), erythrocyte (RBC), twenty-four-hour urine protein quantification (Upr), endogenous creatinine clearance rate, glomerular filtration rate (GFR).Scr, BUN measure with the biochemical instrument automatically of BECKMAN CX4, HGB, RBC T450 Instrument measuring, and glomerular filtration rate (GFR) calculates with the MDRD formula of simplifying.
MDRD formula: GFR (ml/min/1.73m
2)=186 * (serum creatinine)
-1.154* (age)
-0.203* (0.742 women) in this way
Blood fat: TC, TG, HDL, LDL send biochemical chamber to measure with conventional method.
Immunity: CD, IgG, IgA, IgM, C
3, C
4Send biochemical chamber to measure with conventional method.
The content of blood interleukin-6 (IL6), interleukin-2 (IL2) is measured with the ELASA method.
The content of urine transforming growth factor (urine TGF-β) is measured with the ELASA method.
Each indicator-specific statistics method all adopts pairing measurement data t check before and after the treatment; Relatively adopt one factor analysis of variance to judge its significance of difference between each group, do contrast between treatment front and back own control and group, (X ± S) expression uses SPSS11.5 software kit statistics to data with mean ± standard deviation.In the enumeration data statistics, ranked data are analyzed with Ridit, multisample rate relatively use X 2 test, correlation analysis is predicted with regression equation.
The result shows that treatment group total effective rate is 88.67%, apparently higher than matched group 66.03% (P＜0.05), as seen adds on the basis of improving the chronic kidney hypofunction risk factor with Chinese medicine Coryza Treated by Syndrome Differentiation clinical efficacy and obviously improves; Chronic kidney hypofunction patient deficiency-weakness of spleen-QI all in various degree improvement of damp and hot symptom of holding concurrently after treatment group and the treatment of control group, and the therapy of combining Chinese and Western medicine scheme is weak to weak breath, burning sensation during urination is unfavorable, the most outstanding (P＜0.05-0.01) of the clinical efficacy of yellowish fur; Treat the first two group Scr, BUN there was no significant difference (P＞0.05).Illustrate that two groups of chronic kidney hypofunction patients " renal function have comparability before entering clinical observation.Although treatment back two groups of Scr, BUN have decline, the degree that the treatment group descends is more obvious.And the treatment group than treatment of control group after Scr, BUN more significant clinical efficacy is arranged, statistical significance (P＜0.05) is arranged;
Table 11 is two groups of clinical general curative effects relatively (Ridit analyses).Table 12 is hold concurrently variations of damp and hot symptom of deficiency-weakness of spleen-QI before and after two groups of treatments.Table 13 is the variations of renal function index Scr, BUN before and after two groups of treatments
Table 11:
The group produce effects is effectively stablized invalid total total effective rate (%) Ridit
Treatment organizes 9 23 15 6 53 88.67 0.621
Matched group 2 16 17 18 53 66.03# 0.542
Annotate: compare #P＜0.05 with the treatment group;
Table 12:
Treatment group matched group
The preceding treatment back improvement of treatment back improvement rate treatment rate before deficiency-weakness of spleen-QI is held concurrently and treated
(%) (example) (example) be (%) for damp and hot symptom (example) (example)
Lusterless complexion 49 10 79.59 50 18 64.00
Weak 53 5 90.56 53 19 64.15## of weak breath
Thirst but no desire to drink 45 5 88.88 47 17 63.82#
The bitter taste mouth glues 42 7 83.33 40 18 55.00#
Poor appetite abdominal distention 48 6 87.50 45 16 64.44#
Unfavorable 39 3 92.30 44 11 75# of burning sensation during urination
Yellowish fur 53 9 83.01 53 28 47.16##
Annotate: compare #P＜0.05, ##P＜0.01 with matched group;
Table 13:
| Group | N | Scr(μmol/L) | BUN(mmol/L) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 53 53 | 236.98± 115.22 245.32± 117.86 | 200.56±97.51* 243.44±122.63** △ | 11.52±5.06 13.15± 6.20* | 10.51±4.73# 13.00±5.87##△ △ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＜0.05, △ △ P＜0.05 with A group treatment back
Following result has shown the effect of complex of the present invention respectively:
Table 14: the variation of Ccr, 24h urine protein quantitation before and after two groups of treatments (X ± S)
| Group | N | Ccr(ml/min) | 24h urine protein quantitation (g/24h 2) | ||
| Before the treatment | After the treatment | N=47 before the treatment | Treatment back N=47 | ||
| Treatment group A group matched group B group | 50 49 | 37.30±19.11 35.43±18.30 | 40.34±18.47* 33.91± 18.80**△ | 1.31±1.49 0.93±0.75* | 1.12±1.22# 0.85±0.76## △△ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＞0.05, △ △ P＞0.05 with A group treatment back
Treat the first two group Ccr, 24h urine protein quantitation there was no significant difference (P＞0.05).Although do not have difference on the statistics before and after two groups of treatments, the Ccr of treatment group has obvious rising before than treatment, and meaning was even more important Ccr descended after treatment of control group.For two groups of declines that all have in various degree of 24h urine protein quantitation.Be respectively 29.23 ± 13.63 before and after the treatment of GFR (ml/min) treatment group, 34.85 ± 15.17, there were significant differences (P＜0.05) before and after the treatment, be respectively 28.06 ± 14.52 before and after the treatment of control group, 29.53 ± 17.18 (P＞0.05), although treatment group GFR has obvious rising, there is not remarkable type difference between two groups.
Table 15: the variation of two groups of treatment front and back HB, RBC (X ± S)
| Group | N | HB(g/L) | RBC(×10 12/L 2) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 38 38 | 11.12±2.01 11.20±2.41 | 11.62±1.93* 11.05±2.26**△ | 3.54±0.66 3.52±0.88* | 3.63±0.67# 3.54±0.75##△ △ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＞0.05, △ △ P＞0.05 with A group treatment back
Relatively reach before and after two groups of treatments between two groups of treatment back groups relatively, the routine blood test index changes no difference of science of statistics (P＞0.05).
Table 16: the variation of two groups of TC, TG before and after the treatment (X ± S)
| Group | N | TC(mmol/L) | TG(/mmol/L) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 39 39 | 4.87±1.01 4.44±0.75 | 4.58±1.04* 4.47±1.04**△ | 2.52±1.29 2.04±0.92* | 1.81±1.32# 2.59±1.65##△△ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＜0.05;
Compare △ P＞0.05, △ △ P＜0.05 with A group treatment back
Although two groups of cholesterol do not have significant change before and after the treatment, but triglyceride has significant curative effect in the treatment group, and after obviously low and the treatment of control group, statistics has significant difference (P＜0.05), because even more important in the variation meaning of chronic kidney hypofunction patient triglyceride.
Table 17: the variation of two groups of HDL, LDL before and after the treatment (X ± S)
| Group | N | HDL(mmol/L) | LDL(/mmol/L) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 39 39 | 1.15±0.28 1.14±0.29 | 1.21±0.28* 1.13±0.26**△ | 2.85±1.05 2.50±0.70* | 2.17±0.93# 2.81±0.92##△△ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＜0.01;
Compare △ P＞0.05, △ △ P＜0.01 with A group treatment back
Treatment group treatment back high density lipoprotein has rising, although there is not remarkable meaning on the statistics, but low density lipoprotein, LDL has significant curative effect in the treatment group, and after being starkly lower than treatment of control group, statistics has significant differences (P＜0.01), illustrates that clearing away heat and eliminating dampness Chinese medicine can improve chronic kidney hypofunction patient lipid metabolism significantly.
Table 18: the variation of two groups of blood UA, urine TGF-β before and after the treatment (X ± S)
| Group | N | UA(umol/L) | TGF-β(ug/L) | ||
| Before the treatment | After the treatment | N=31 before the treatment | Treatment back N=31 | ||
| Treatment group A group matched group B group | 34 34 | 487.69± 157.62 493.83± 105.36 | 462.98±133.92* 491.49±115.63** △ | 2.31±0.52 2.42±0.51 | 2.00±0.31# 2.04±0.43##△△ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＜0.01 is compared with the treatment of B group is preceding in #P＜0.01;
Compare △ P＞0.05, △ △ P＞0.05 with A group treatment back
Relatively reach before and after two groups of treatments between two groups of treatment back groups relatively, the blood uric acid index does not have significant change (P＞0.05).And all have significant change before and after two groups of treatments of urine transforming growth factor, therapy of combining Chinese and Western medicine scheme and single effect that all has obvious inhibition urine transforming growth factor excessively to generate with Western medicine control chronic kidney hypofunction risk factor are described.
Table 19: the variation of two groups of blood IL-2, IL-6 before and after the treatment (X ± S)
| Group | N | IL-2 | IL-6 | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 31 31 | 68.40±11.21 72.45±2.71 | 71.52±14.77* 57.01±15.85**△ | 78.69±90.46 85.37±158.26 | 39.33±27.32# 72.84±106.85##△ △ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＜0.01;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＜0.05;
Compare △ P＜0.01, △ △ P＞0.05 with A group treatment back
The treatment group has the effect of rising to the blood interleukin-2, although there is not the significance,statistical meaning, and not only the do not raise effect of interleukin-2 of matched group also makes interleukin-2 reduce, and statistical significance is arranged, and therefore two groups have significance difference (P＜0.01) after treatment.The treatment group has effect P＜0.05 of remarkable reduction blood interleukin-6, although matched group also has the reduction effect, does not have statistical significance.
Table 20: the variation of two groups of CD, IgG before and after the treatment (X ± S)
| Group | N | CD(g/L) | IgG | ||
| Before the treatment | Treatment back difference | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 35 35 | 74.85±10.79 73.22±9.64 | 79.81±9.01* 74.51±8.79** △ | 12.25±3.39 11.99±2.93 | 11.77±3.31# 11.39±2.61## △△ |
Annotate: compare before treating with the A group, * P＜0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＜0.05, △ △ P＞0.05 with A group treatment back
The treatment group cellular immune function that is significantly improved, total garland has significant increase because it makes blood, and has compared significant statistical significance after the treatment of control group.And the IgG that embodies humoral immune function does not have significant effect for two groups.
Table 21: the variation of two groups of IgM, IgA before and after the treatment (X ± S)
| Group | N | IgM | IgA | ||
| Before the treatment | Treatment back difference | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 35 35 | 1.11±0.50 1.07±0.57 | 1.09±0.43* 1.00±0.55** △ | 2.26±1.11 2.52±1.21 | 2.18±1.06# 2.30±0.91##△ △ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＞0.05, △ △ P＞0.05 with A group treatment back
Table 22: two groups of C before and after the treatment
3, C
4Variation (X ± S)
| Group | N | C 3 | C 4 | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Treatment group A group matched group B group | 35 35 | 0.83±0.22 0.80±0.28 | 0.88±0.21* 0.80±0.25** △ | 0.25±0.06 0.27±0.11 | 0.27±0.07# 0.26±0.12##△ △ |
Annotate: compare before treating with the A group, * P＞0.05, relatively preceding with the treatment of B group, * * P＞0.05;
Treat preceding the comparison with the A group, ##P＞0.05 is compared with the treatment of B group is preceding in #P＞0.05;
Compare △ P＞0.05, △ △ P＞0.05 with A group treatment back
The above results shows that therapy of combining Chinese and Western medicine scheme and western medical treatment scheme are to chronic kidney hypofunction patient IgM, IgA, C
3, C
4Not significantly influence, IgM, IgA, the C of two groups of treatment front and back
3, C
4There was no significant difference (P＞0.05).
Claims (5)
1, a kind of medicinal composition for the treatment of chronic kidney hypofunction is characterized in that making (every pair of Chinese medicine) by the following weight Chinese medicinal raw materials: Radix Codonopsis 5-30 gram, Radix Astragali 5-45 gram, Fructus Tsaoko 3-20 gram, Rhizoma Atractylodis 5-30 gram, Rhizoma Coptidis 3-12 gram, Radix et Rhizoma Rhei (processed) 3-30 gram.
2, by the medicinal composition of the described treatment chronic kidney hypofunction of claim 1, it is characterized in that making: Radix Codonopsis 15 grams, Radix Astragali 15 grams, Fructus Tsaoko 6 grams, Rhizoma Atractylodis 10 grams, Rhizoma Coptidis 3 grams, Radix et Rhizoma Rhei (processed) 9 grams by following weight proportioning raw material of Chinese medicine.
3, by the medicinal composition of the described treatment chronic kidney hypofunction of claim 1, it is characterized in that also can adopting the Chinese medicine alternative materials preparation of following weight proportioning: Radix Pseudostellariae 5-30 gram, Rhizoma Atractylodis Macrocephalae 10-45 gram, Magnolia officinalis Rehd. et wils. 5-30 gram, Fructus Amomi gram 3-12, Semen Plantaginis 10-45 gram, Radix Et Rhizoma Rhei 3-15 gram.
4, the medicinal composition of claim 1 or 2 or 3 described treatment chronic kidney hypofunctions, it is characterized in that by following method fried: adopt ceramic earth pot or enamel enamelware pot, get the raw material of Chinese medicine of required weight, use cold water soak 30 minutes before frying in shallow oil, the water yield slightly exceeds the medicine one-inch, the then corresponding minimizing of water of two juice, fry in shallow oil for a long time with slow fire, a juice was fried in shallow oil 25 minutes, and two juice were fried in shallow oil 15-20 minute, head, two juice mix, divide and take for 2-3 time, each 100ml-150ml, children's reduces by half, Semen Plantaginis is decocted a drug wrapped with gauze in the medicine, and Radix Et Rhizoma Rhei need head is fried in shallow oil to finish and put in preceding 10 minutes.
5, by the medicinal composition of claim 1 or 2 or 3 described treatment chronic kidney hypofunctions, it is characterized in that described chronic kidney hypofunction is insufficiency of the spleen damp-heat type chronic renal failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100289737A CN100355445C (en) | 2005-08-19 | 2005-08-19 | Medicine composition for treating chronic renal failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100289737A CN100355445C (en) | 2005-08-19 | 2005-08-19 | Medicine composition for treating chronic renal failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733279A true CN1733279A (en) | 2006-02-15 |
| CN100355445C CN100355445C (en) | 2007-12-19 |
Family
ID=36076034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100289737A Expired - Fee Related CN100355445C (en) | 2005-08-19 | 2005-08-19 | Medicine composition for treating chronic renal failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100355445C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100770634B1 (en) | 2006-08-17 | 2007-10-26 | 박용기 | Pharmaceutical composition for the prevention and treatment of kidney failure |
| CN101607076B (en) * | 2009-07-24 | 2011-06-29 | 崔延昌 | Traditional Chinese medicine for treating uraemia |
| CN102240358A (en) * | 2011-06-02 | 2011-11-16 | 杨晓庆 | Chinese medicinal blood fat removing and blood stasis eliminating mixture for treating hyperlipemia |
| CN101926491B (en) * | 2010-02-02 | 2012-11-28 | 贵州三元太宝实业股份有限公司 | White atractylodes health-care beverage and preparation method thereof |
| CN102846948A (en) * | 2012-08-30 | 2013-01-02 | 李亚萍 | Decoction medicine used for treating proteinuria caused by spleen asthenia and qi stagnation |
| CN108295239A (en) * | 2018-01-04 | 2018-07-20 | 杨雪军 | Treatment albumen urinates Chinese medicine composition and its preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1287848C (en) * | 2003-11-21 | 2006-12-06 | 金良田 | Kidney failure resistant formula and its preparation process |
-
2005
- 2005-08-19 CN CNB2005100289737A patent/CN100355445C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100770634B1 (en) | 2006-08-17 | 2007-10-26 | 박용기 | Pharmaceutical composition for the prevention and treatment of kidney failure |
| CN101607076B (en) * | 2009-07-24 | 2011-06-29 | 崔延昌 | Traditional Chinese medicine for treating uraemia |
| CN101926491B (en) * | 2010-02-02 | 2012-11-28 | 贵州三元太宝实业股份有限公司 | White atractylodes health-care beverage and preparation method thereof |
| CN102240358A (en) * | 2011-06-02 | 2011-11-16 | 杨晓庆 | Chinese medicinal blood fat removing and blood stasis eliminating mixture for treating hyperlipemia |
| CN102240358B (en) * | 2011-06-02 | 2012-09-05 | 胡翠娟 | Chinese medicinal blood fat removing and blood stasis eliminating mixture for treating hyperlipemia |
| CN102846948A (en) * | 2012-08-30 | 2013-01-02 | 李亚萍 | Decoction medicine used for treating proteinuria caused by spleen asthenia and qi stagnation |
| CN108295239A (en) * | 2018-01-04 | 2018-07-20 | 杨雪军 | Treatment albumen urinates Chinese medicine composition and its preparation method and application |
| CN108295239B (en) * | 2018-01-04 | 2021-10-22 | 上海复活石医药科技有限公司 | Traditional Chinese medicine composition for treating proteinuria and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100355445C (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1954825A (en) | Supermicro Tongxinluo Chinese herbal composite and its new usage | |
| CN1733279A (en) | A kind of medicinal composition for the treatment of chronic kidney hypofunction | |
| CN1290553C (en) | Pharmaceutical composition for treating menorrhagia and method for preparing the same | |
| CN1323689C (en) | Medicine for treating prostatic accrementition and its preparation | |
| CN1586533A (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN101049293A (en) | Medication composition of acetyl cysteine or its pharmaceutical salt and asarin | |
| CN1652805A (en) | A herbal composition for treating and improving bronchial dyspnea | |
| CN1579455A (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
| CN1899315A (en) | Developing method for Chinese medicine compound secondary new medicine | |
| CN1380081A (en) | Chinese medicine preparation containing curculigo rhizome and epimedium and its preparation method | |
| CN1500517A (en) | Chinese traditional medicine composition for chronic nephritis, its preparation method and quality control method | |
| CN1548156A (en) | Hepatitis B treating vaccine prepn and its prepn process and use | |
| CN1631895A (en) | Preparation method of amygdalin and its application in preparation of amygdalin preparation for promoting the blood circulation of heart, brain, pancreas and wound | |
| CN1557395A (en) | A kind of Qingluo Tongbi preparation for treating rheumatoid arthritis and its preparation method | |
| CN1634302A (en) | Medicine for treating gout, hyperuricemia and hyperlipidemia and preparation method thereof | |
| CN1846724A (en) | A pharmaceutical composition for treating nephropathy and its preparation method | |
| CN1509739A (en) | Chinese medicinal composition for chronic primary glomerulonephritis and its preparation and quality control | |
| CN1616012A (en) | Chinese medicine preparation for treating hepatitis and its preparing and detecting method | |
| CN1709436A (en) | Yinzhihuang tablet of oriental wormwood, cape jasmine and baicalin, and its preparing and detecting method | |
| CN1593500A (en) | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat | |
| CN1631413A (en) | Medicine for treating chronic colitis and its preparing process | |
| CN1267132C (en) | Aloes extractive and use in preparation for treating astriction | |
| CN1631418A (en) | A kind of medicine for treating chronic nonspecific ulcerative colitis and its preparation method | |
| CN1872258A (en) | Chinese traditional medicine for treating chronic hepatitis, and preparation method | |
| CN1509732A (en) | Chinese medicine for treating coronary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071219 Termination date: 20180819 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |